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INTRODUCTION
Next generation sequencing (NGS) and other high-throughput techniques led to the discovery of numerous recurrently mutated genes in acute myeloid leukemia (AML). [1] [2] [3] The Cancer Genome Atlas (TCGA) consortium studied 200 AML patients by whole-genome or whole-exome sequencing (WGS/WES), and identified 23 genes as "significantly mutated" at a higher-thanexpected frequency. 4 Although the functional consequences of many novel recurrent genetic alterations are not yet fully understood, these mutations may become clinically useful molecular markers for diagnosis, prognostication, prediction of treatment response, or disease monitoring.
Furthermore, defining the spectrum and patterns of driver gene mutations in AML patients is an important step to identify relevant targets for new treatment approaches. Simultaneously, the increasing number of genes known to be mutated at intermediate or low frequencies leads to a complex interplay of genetic changes that can only be analyzed in sufficiently large cohorts.
Therefore, we set out to comprehensively characterize the spectrum and clinical relevance of recurrent driver gene mutations in a large, well-characterized, and homogenously treated group of AML patients.
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SUBJECTS AND METHODS

Patients
We studied 664 previously untreated AML patients who received intensive induction chemotherapy on two randomized multicenter phase III trials of the German AML Cooperative Group (AMLCG) between 1999 and 2012 (AMLCG-1999, clinicaltrials.gov identifier NCT00266136, n=390; and AMLCG-2008, NCT01382147, n=274). [5] [6] [7] [8] Treatment regimens are described in the Supplement. Patients were included in this study if a suitable bone marrow (BM) or peripheral blood (PB) specimen was available. The diagnosis of AML was based on World
Health Organization (WHO) criteria. Cytogenetic risk groups were defined according to the Medical Research Council (MRC) classification. 9 All study protocols were in accordance with the Declaration of Helsinki and approved by the institutional review boards of the participating centers. All patients provided written informed consent for inclusion on the clinical trial and genetic analyses.
Targeted sequencing
We studied 68 genes recurrently mutated in myeloid malignancies (Supplemental Tables 1 and   2 ). Mononuclear cells were enriched from pretreatment BM or PB by Ficoll density gradient centrifugation. We sequenced the entire coding sequences of 37 genes and recurrently mutated regions 4,10 in 31 genes, using a custom amplicon-based targeted enrichment assay (Haloplex, Agilent, Boeblingen, Germany) and an Illumina MiSeq instrument (Illumina, San Diego, CA, USA). Criteria used to differentiate leukemia-associated driver mutations from germline variants are detailed in the Supplemental Methods and in Supplemental Figure 1 . Mutations in NPM1 and CEBPA, FLT3 internal tandem duplications (FLT3-ITD) and KMT2A (formerly MLL) partial tandem duplications (KMT2A-PTD) were also tested using standard methods. 11, 12 For personal use only. on October 4, 2017. by guest www.bloodjournal.org From
Statistical analyses
We studied associations between different gene mutations, and between gene mutations and other patient characteristics, using Fisher's exact test for categorical and the Wilcoxon rank-sum test for continuous variables, with adjustment for multiple testing using the Benjamini-Hochberg method. Analyses of treatment outcomes used commonly accepted definitions of complete remission (CR), relapse-free survival (RFS) and overall survival (OS) (Supplemental Methods). 13 For survival endpoints, P values were calculated from Cox proportional hazards model stratified for trial arm, using the Wald test. Multivariate models were used to integrate known clinical and genetic risk factors and potential confounders (Supplemental Methods). To account for baseline differences (Supplemental Table 3 ) and different recruitment periods of the two clinical trial cohorts, all outcome analyses were adjusted for trial and treatment arm. Statistical analyses were performed using R version 3.2.2 (R Foundation for Statistical Computing, Vienna, Austria).
For
RESULTS
Spectrum of driver mutations in adult AML
The median age of the 664 patients was 57 years (range, 18-86 years). Other baseline characteristics are listed in Table 1 . The mean sequencing coverage of the target region across all samples was 430-fold, and on average, 96% of the target region was covered at >30x. We identified a total of 2395 driver gene mutations in 59 different genes (Supplemental Table 4A ).
Forty-eight genes were recurrently mutated, 35 genes were mutated in >1% of patients, and 10 genes were mutated in >10% ( Figure 1A At least one driver mutation was identified in 97% of patients (646/664). Of the remaining 18 patients, 15 had a recurrent balanced chromosomal translocation resulting in a known fusion transcript. Thus, ≥ 1 molecularly defined driver lesion was detected in 99.5% of patients. The median number of mutations per patient was 4 (range, 0-10; Supplemental Figure 3) , and the median number of mutated genes was 3 (range, 0-9). The number of mutated driver genes increased with age ( Figure 1B ; P<.001 for association with age as a continuous variable).
Patients with MRC intermediate-risk cytogenetics had a higher number of mutated driver genes (median, 4) than in those with favorable or adverse cytogenetics (median, 1 and 2 mutated genes, respectively) ( Figure 1C ). Finally, patients with secondary AML after an antecedent hematological disorder (sAML) had more, and patients with treatment-related AML (tAML) fewer mutations in genes covered by our panel, compared to those with de novo AML ( Figure 1D 
Differences in variant allele frequencies between driver genes
The median variant allele frequency (VAF) of driver gene mutations was 0.36, significantly lower than the VAFs of heterozygous germline polymorphisms (median, 0.50; Supplemental Figure 4 ). and PTPN11 tended to be more frequent in sAML compared to de novo AML, while TP53 mutations were more common in patients with tAML. However, none of these associations between individual gene mutations and sAML/tAML was significant at q<.01, and no single mutation was highly specific for sAML or tAML in our cohort. Figure 4A ). Of the 664 patients, 503 (76%) had exactly one of these lesions.
Only 16 patients (2.4%) carried more than one of these changes, and 145 patients (22%) did not harbor any of the aforementioned genetic alterations and thus could not be assigned to one of 
Driver mutations and survival
We studied the associations of driver mutations found in ≥ 20 patients (≥3%) with treatment outcomes. The median OS of our patient cohort was 17.8 months, and the median follow-up for survivors was 58 months. Univariate analyses of gene mutations and OS are reported in Supplemental Table 6 . Patients with mutated NPM1, particularly in the absence of FLT3-ITD, and those with double CEBPA mutations had relatively favorable OS, while survival was significantly shorter for patients carrying mutations in DNMT3A, RUNX1, ASXL1, SRSF2, TP53, BCOR, U2AF1 or SF3B1 (Supplemental Figure 5) . However, these analyses may be biased since some gene mutations tended to co-occur, or showed associations with other prognostic markers including age and cytogenetics.
To account for the complex interrelations between gene mutations and other known risk factors, we constructed multivariate models. Since the frequency of several gene mutations differed between younger (<60 years) and older (≥60 years) patients, and treatment intensity was higher in younger patients, we also tested for interactions between each individual gene mutation and age. In a multivariate model for OS (Table 2) , age <60 years, favorable cytogenetics, mutated NPM1 in the absence of FLT3-ITD and, in trend, double CEBPA mutations associated with longer OS. The prognostic impact of DNMT3A and RUNX1 mutations differed significantly between younger and older patients. Both mutations associated with inferior OS only among younger, but not among older patients. Therapy-related AML, decreased performance status, higher leukocyte counts, adverse cytogenetic changes and TP53 mutations all associated with shorter OS regardless of age group. Mutations in both genes were also linked to shorter RFS, and no interactions with age group were observed for this end point.
Prognostic impact of gene mutations in defined age groups and cytogenetic subsets.
Mutations in certain genes were closely associated with defined, prognostically distinct cytogenetic subgroups. Furthermore, multivariate analyses revealed the impact of some mutations depends on patient age. To facilitate interpretation of these results and visualize the combined effects of co-occurring gene mutations on survival, we analyzed patient subsets stratified according to age and cytogenetics.
The three most common driver mutations in our cohort were strongly enriched in patients with Figure 5A,B) . Of note, no survival differences were observed between DNMT3A codon R882 and other DNMT3A mutations (data not shown). 16 On the other hand, NPM1 mutations associated with favorable OS only among older patients ( Figure 5C ,D). When both mutations were analyzed jointly, DNMT3A mutations remained an unfavorable prognostic factor in younger patients, and NPM1 mutations associated with favorable OS among older patients ( Figure 5E ,F).
While there was no statistically significant interaction between the two mutations, patients with mutated NPM1 and wild-type DNMT3A had the most favorable outcomes in both age groups. 
with complex karyotypes, but in only 1.5% (8/539) of patients with non-adverse karyotypes.
TP53-mutated patients had significantly shorter OS compared to patients with complex karyotypes or non-complex adverse cytogenetics without TP53 mutations (Figure 7 
DISCUSSION
Our study presents comprehensive information on the incidence, patterns of co-mutation, clinical correlations and prognostic relevance of mutations in 68 recurrently mutated genes in adult AML. To our knowledge, together with another study published in abstract form, 17 our work represents one of the largest patient cohorts characterized for an extensive set of known driver mutations, including the 23 "significantly mutated" genes identified by the TCGA consortium. 4 Our study included intensively treated patients across a broad age range, including patients aged ≥ 60 years who are fit for intensive therapy, a clinically important population not included or underrepresented in other cohorts. [17] [18] [19] Further strengths of our study include the fact that all patients received comparable treatment on two consecutive phase III trials, and the long duration of follow-up.
At least one genetic driver event was identified in >99% of patients when mutations and balanced translocations were combined. As reported in previous studies, patients with favorable or unfavourable abnormal cytogenetics, and particularly those with balanced translocations, had a lower number of additional gene mutations compared to those with cytogenetically normal AML or intermediate-risk abnormalities. 18 Fusion genes are strong oncogenic drivers apparently requiring relatively few cooperating events. Patients with sAML had a larger number of mutated genes compared to de novo disease, possibly reflecting the stepwise gain of mutations during the evolution of myelodysplastic syndromes (MDS) or myeloproliferative neoplasms to AML.
20,21
The number of driver gene mutations increased with age, even after adjustment for the higher proportion of sAML and the lower incidence of CBF translocations in older patients (data not shown). Older patients also were more likely to carry alterations in specific genes including TET2, RUNX1 and ASXL1, as previously reported, [22] [23] [24] [25] [26] [27] and SRSF2, genes that have recently been implicated in age-related clonal hematopoiesis. 28 These data contribute to our understanding of differences in AML biology between younger and older patients. Coleman
Lindsley and colleagues recently reported that mutations in eight different genes are highly specific for sAML, based on a comparison of rigorously selected sAML and de novo AML patients. 21 In our cohort, we only identified a modest association between clinically reported sAML and mutations in four of these genes, namely SRSF2, ASXL1, STAG2, and U2AF1. Of note, Coleman-Lindsley and coworkers also found secondary-type mutations in one-third of patients in an unselected older cohort with clinically defined de novo AML. Emerging data suggest that age-related clonal hematopoiesis, clonal cytopenias of undetermined significance and MDS form a spectrum of related conditions. 29 Thus, some of the "de novo" AML patients in our report and in the unselected patient cohort studied by Coleman Lindsley may in fact have had preexisting clonal hematopoiesis or undiagnosed MDS. It remains to be determined whether a genetic definition of "secondary-type" AML is more relevant with regard to outcomes than an sAML diagnosis based on clinical history.
Our findings regarding the mutational landscape of adult AML are largely consistent with the TCGA consortium's WES and WGS data, with FLT3, NPM1 and DNMT3A identified as the most commonly mutated genes. 4 We noted a higher prevalence of NRAS and KRAS mutations (26%) compared to the TCGA cohort (12%), a discrepancy potentially explained by the often low VAF of these mutations and the deeper sequencing coverage achieved by our targeted sequencing approach. Overall, 21% of driver mutations in our study had VAFs <10%, and such variants mutated in >10%. 18 The low frequency of RUNX1 and TET2 and the relatively high frequency of CEBPA and KIT mutations in the Japanese cohort may be due to its younger age range.
Mutations in NPM1 (19.2%) and DNMT3A (16%) also were found more rarely compared to our
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NGS techniques allow estimating the proportion of cells in a specimen carrying a somatic mutation based on its allele frequency. We observed that mutations in some genes, including the epigenetic modifiers DNMT3A, TET2 and IDH2, frequently had VAFs close to 50%. This indicates they were usually present in a large majority of cells, consistent with the concept that these mutations constitute early, and potentially initiating, events during leukemogenesis. 31, 32 On the other hand, activating mutations in growth factor signaling pathways (e.g., FLT3, KIT, NRAS
and KRAS mutations) commonly had lower VAFs. These changes apparently occur relatively late during the evolution of the malignant clone, a conclusion supported by analyses of paired diagnosis and relapse samples showing that FLT3 and RAS mutations are frequently lost during disease progression. 33 We used VAFs corrected for copy number alterations to obtain a measure of the fraction of cells carrying each variant. Our assay did not allow us to detect possible copy-neutral loss of heterozygosity, yet this seems to be a relatively rare phenomenon in AML. 34 Although the number of somatic variants identified through targeted sequencing is not sufficient to infer the precise clonal architecture in individual patients, our findings have implications for the development of targeted therapies aimed at eradicating the malignant "founder clone".
Our study confirms previously reported associations of co-occurring driver mutations, e.g.
between mutations in DNMT3A, NPM1 and FLT3, 4 between double CEBPA and GATA2 mutations, 35 and between RUNX1 and ASXL1 mutations. 23 Contrary to a recently published study suggesting a link between CSF3R p.T618I and biallelic CEBPA mutations, we found only one CSF3R mutation among 27 CEBPA double-mutated patients. 36 We also identified associations that, to our knowledge, have not been described in AML before, including frequent 45 We found that patients with >5 mutated genes had inferior survival in univariate analyses (Supplemental Results), but not in multivariate models accounting for individual gene mutations and cytogenetics. Thus, the prognostic impact of specific driver gene mutations apparently outweighs the impact of total mutation number.
Integrating the prognostic information provided by gene mutations, cytogenetics, and other markers into clinically applicable risk stratification algorithms is an important, yet challenging task. Several groups have proposed novel risk stratification schemes for AML based on gene mutations alone or in combination with other risk factors. 18, 19, 43 In comparison to our work, these studies focused on smaller sets of commonly mutated genes. Our cohort size was not sufficient to establish and independently validate another new molecular risk classification encompassing not only high-but also intermediate-frequency markers. Integration of the accumulating For personal use only. on October 4, 2017. by guest www.bloodjournal.org From information on genetic risk factors in AML into clinically applicable algorithms should occur through collaboration of multiple study groups to increase sample size and validity.
One limitation of our study is that we focused on a predefined set of recurrently mutated genes, and not the entire coding sequence was analyzed for genes with well-defined "hotspots".
However, our assay covered 99% of the mutations in the 68 target genes that were found in the TCGA cohort. WES or WGS remain the preferred approaches for comprehensive mutation analyses. However, genome-wide somatic variant calling requires matched germline DNA, and suitable non-leukemic tissue wasn't available for our patients.
In summary, our study offers a detailed survey of recurrent driver gene mutations in one of the largest, well-characterized and uniformly treated adult AML cohorts analyzed so far. We provide detailed insights into patterns of gene mutations, their clinical correlations and their prognostic relevance. We hope our work will serve as an important reference for future research on AML pathogenesis, and as a starting point for a new, genetically based disease classification that will contribute to improved risk stratification and, ultimately, better treatment results. 
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